Tedizolid Suppressive Antimicrobial Therapy in a Reference Center

Completed

• Conditions: Bone and Joint Infection
• Interventions: Other: patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

• Registration Number: NCT04662736
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-11-25
• Study First Submitted QC: 2020-12-04
• Study First Posted: 2020-12-10
• Study Start: 2021-02-01
• Primary Completion: 2021-02-01
• Study Completion: 2021-04-01
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-15
• Last Update Posted: 2021-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy

Read More

Exclusion Criteria

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy	patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy	-

Primary Outcome Measures

Name	Time	Method
rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy	between 2016 and 2021	proportion of patients having tedizolid as a suppressive antibiotic therapy
rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic	2 years	proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy
rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive	through study completion, an average of 1 year	proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy
Description of patients having had a BJI/PJI treated with tedizolid as a suppressive	2 years	type of patients: age, CMI, comorbidities...
Description of BJI/PJI treated with tedizolid as a suppressive	2 years	implant or prothese or not, acute/ chronic, bacteriology

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France